Overview

A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers

Status:
Not yet recruiting
Trial end date:
2022-01-22
Target enrollment:
Participant gender:
Summary
The study is a single-centre, open-label, fixed-sequence, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects. Subjects will take SHR2150 on Day 1 and Day 21, and take efavirenz from Day 7 to Day 26.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Efavirenz